Drug Profile

TERN 501

Alternative Names: TERN-501

Latest Information Update: 26 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Terns Pharmaceuticals
Class Anti-inflammatories; Hepatoprotectants; Obesity therapies; Small molecules
Mechanism of Action Thyroid hormone receptor beta agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

Phase II Non-alcoholic steatohepatitis
Preclinical Obesity

Most Recent Events

21 Jun 2024 Pharmacodynamics data from a preclinical trial in Obesity released by Terns Pharmaceuticals
20 May 2024 Preclinical trials in Obesity in USA (PO) before May 2023
31 Dec 2023 Terns Pharmaceuticals has patent protection for TERN 501 in USA, China, Chile, and Russia, as at December 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com